The novel therapeutic strategy of the MErCuRIC trial investigates the combination of a MET and a MEK inhibitor to combat metastasis, improve survival, and potentially develop a new clinical intervention approach in patients with this poor‐prognosis subtype of CRC. Here, MET is linked to colorectal carcinoma.